MA
Therapeutic Areas
Natco Pharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Lenalidomide (Naxlen) | Multiple Myeloma, Myelodysplastic Syndromes | Approved |
| Sofosbuvir + Velpatasvir (Hepcvir-V) | Hepatitis C Virus (HCV) | Approved |
| Ledipasvir + Sofosbuvir | Hepatitis C Virus (HCV) | Approved |
| Tamoxifen | Breast Cancer | Approved |
| Capecitabine | Colorectal Cancer, Breast Cancer | Approved |
| Imatinib | Chronic Myeloid Leukemia (CML) | Approved |
| Olaparib | Ovarian Cancer, Breast Cancer (BRCA-mutated) | ANDA Filed |
| Lenalidomide (Revlimid Generic) | Multiple Myeloma | ANDA Filed |
Leadership Team at Natco Pharma
VN
V.C. Nannapaneni
Chairman & Managing Director
RN
Rajeev Nannapaneni
Vice Chairman & CEO
PB
P. Bhaskara Narayana
Chief Financial Officer
DR
D. Rajkumar
Whole-time Director
DG
Dr. G. S. Prasad
Independent Director
MS
M. S. Mohan
Independent Director
PV
P. V. R. K. Prasad
Independent Director
VS
V. S. R. Sastry
Independent Director
DK
Dr. K. V. Subrahmanyam
Independent Director